GlobeNewswire: Ultragenyx Pharmaceutical Inc. Contains the last 10 of 472 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:33:51ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/22/2851131/0/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=15920Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2024-03-22T20:00:00Z<![CDATA[NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 13,020 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of March 18, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/02/27/2836492/0/en/Ultragenyx-to-Participate-at-Investor-Conferences-in-March.html?f=22&fvtc=4&fvtv=15920Ultragenyx to Participate at Investor Conferences in March2024-02-27T21:30:00Z<![CDATA[44th Annual Cowen Healthcare Conference on March 4]]>https://www.globenewswire.com/news-release/2024/02/23/2834646/0/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=15920Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2024-02-23T21:05:00Z<![CDATA[NOVATO, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 10,995 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of February 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/02/15/2830348/0/en/Ultragenyx-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Update.html?f=22&fvtc=4&fvtv=15920Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update2024-02-15T21:01:00Z<![CDATA[2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million]]>https://www.globenewswire.com/news-release/2024/02/08/2826418/0/en/Ultragenyx-to-Host-Conference-Call-for-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Update.html?f=22&fvtc=4&fvtv=15920Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update2024-02-08T21:00:00Z<![CDATA[NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 15, 2024, to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/06/2824223/0/en/Ultragenyx-Announces-Data-Demonstrating-Treatment-with-UX111-Results-in-Significant-Reduction-in-Heparan-Sulfate-Exposure-in-Cerebrospinal-Fluid-Correlated-with-Improved-Long-term-.html?f=22&fvtc=4&fvtv=15920Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)2024-02-06T13:00:00Z<![CDATA[The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2024 The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium™ 2024]]>https://www.globenewswire.com/news-release/2024/02/05/2823853/0/en/Ultragenyx-Receives-PRIME-Designation-from-European-Medicines-Agency-EMA-for-GTX-102-for-the-Treatment-of-Angelman-Syndrome.html?f=22&fvtc=4&fvtv=15920Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome2024-02-05T21:05:00Z<![CDATA[GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation]]>https://www.globenewswire.com/news-release/2024/01/31/2821048/0/es/Ultragenyx-anuncia-la-aprobaci%C3%B3n-de-Dojolvi-triheptano%C3%ADna-para-su-inclusi%C3%B3n-en-el-Compendio-Nacional-de-Insumos-para-la-Salud-de-M%C3%A9xico-en-el-tratamiento-de-los-trastornos-de-oxida.html?f=22&fvtc=4&fvtv=15920Ultragenyx anuncia la aprobación de Dojolvi® (triheptanoína) para su inclusión en el Compendio Nacional de Insumos para la Salud de México en el tratamiento de los trastornos de oxidación de ácidos grasos de cadena larga (LC-FAOD)2024-01-31T13:00:00Z<![CDATA[Dojolvi® (triheptanoína) es la única terapia aprobada para este raro trastorno metabólico potencialmente mortal Dojolvi® (triheptanoína) es la única terapia aprobada para este raro trastorno metabólico potencialmente mortal]]>https://www.globenewswire.com/news-release/2024/01/25/2817385/0/en/Ultragenyx-Announces-Completion-of-Dosing-Across-Stage-1-Cohorts-in-Pivotal-Phase-1-2-3-Cyprus2-Study-Evaluating-UX701-Gene-Therapy-for-the-Treatment-of-Wilson-Disease.html?f=22&fvtc=4&fvtv=15920Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease2024-01-25T21:05:00Z<![CDATA[Safety and initial efficacy data from Stage 1 expected in the first half of 2024]]>https://www.globenewswire.com/news-release/2024/01/19/2812494/0/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=15920Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2024-01-19T21:00:00Z<![CDATA[NOVATO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 12,130 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of January 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).]]>